P09 Stock Overview
Designs, develops, and manufactures sequencing solution to resolve genetically complex problems. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Pacific Biosciences of California, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.86 |
| 52 Week High | US$9.40 |
| 52 Week Low | US$1.05 |
| Beta | 2.01 |
| 11 Month Change | 2.31% |
| 3 Month Change | 42.61% |
| 1 Year Change | -69.01% |
| 33 Year Change | -92.26% |
| 5 Year Change | -60.48% |
| Change since IPO | -84.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| P09 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -18.7% | 1.7% | -0.2% |
| 1Y | -69.0% | 9.0% | 7.8% |
Return vs Industry: P09 underperformed the German Life Sciences industry which returned 10.6% over the past year.
Return vs Market: P09 underperformed the German Market which returned 9% over the past year.
Price Volatility
| P09 volatility | |
|---|---|
| P09 Average Weekly Movement | 19.0% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: P09's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: P09's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 796 | Christian O. Henry | www.pacb.com |
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides.
Pacific Biosciences of California, Inc. Fundamentals Summary
| P09 fundamental statistics | |
|---|---|
| Market cap | €565.95m |
| Earnings (TTM) | -€371.30m |
| Revenue (TTM) | €163.07m |
3.5x
P/S Ratio-1.5x
P/E RatioIs P09 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| P09 income statement (TTM) | |
|---|---|
| Revenue | US$173.15m |
| Cost of Revenue | US$118.87m |
| Gross Profit | US$54.28m |
| Other Expenses | US$448.52m |
| Earnings | -US$394.24m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.45 |
| Gross Margin | 31.35% |
| Net Profit Margin | -227.69% |
| Debt/Equity Ratio | 197.1% |
How did P09 perform over the long term?
See historical performance and comparison